102 related articles for article (PubMed ID: 38717385)
1. Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy.
Rapoport BL; Anderson R
Immunotherapy; 2024 May; ():. PubMed ID: 38717385
[No Abstract] [Full Text] [Related]
2. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.
Marabelle A; Gray J
Pediatr Blood Cancer; 2015 Aug; 62(8):1317-25. PubMed ID: 25808079
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
6. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
Li T; Liu T; Zhu W; Xie S; Zhao Z; Feng B; Guo H; Yang R
Clin Med Insights Oncol; 2021; 15():11795549211035540. PubMed ID: 34408525
[TBL] [Abstract][Full Text] [Related]
7. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
8. Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma.
Pérez-Lorenzo R; Erjavec SO; Christiano AM; Clynes R
Oncotarget; 2021 Jan; 12(2):66-80. PubMed ID: 33520112
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.
Ritu ; Chandra P; Das A
Clin Exp Med; 2023 Dec; 23(8):4297-4322. PubMed ID: 37804358
[TBL] [Abstract][Full Text] [Related]
10. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
11. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
[TBL] [Abstract][Full Text] [Related]
12. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
13. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.
Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D
JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade for hematologic malignancies: a review.
Pianko MJ; Liu Y; Bagchi S; Lesokhin AM
Stem Cell Investig; 2017; 4():32. PubMed ID: 28529947
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
17. Innovative Therapy, Monoclonal Antibodies and Beyond.
Di Nicola M; Apetoh L; Bellone M; Colombo MP; Dotti G; Ferrone S; Muscolini M; Hiscott J; Anichini A; Pupa SM; Braud F; Del Vecchio M
Cytokine Growth Factor Rev; 2017 Dec; 38():1-9. PubMed ID: 29029813
[TBL] [Abstract][Full Text] [Related]
18. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Varricchi G; Loffredo S; Marone G; Modestino L; Fallahi P; Ferrari SM; de Paulis A; Antonelli A; Galdiero MR
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412566
[TBL] [Abstract][Full Text] [Related]
19. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W; Gilligan BM; Yuan J; Li T
J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
[TBL] [Abstract][Full Text] [Related]
20. Functionally Masked Antibody to Uncouple Immune-Related Toxicities in Checkpoint Blockade Cancer Therapy.
Song SH; Ghosh T; You DG; Joo H; Lee J; Lee J; Kim CH; Jeon J; Shin S; Park JH
ACS Nano; 2023 Jun; 17(11):10065-10077. PubMed ID: 37184643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]